What is PTT considering doing with its stake in Taiwan-listed Lotus Pharmaceutical, and what is the strategic rationale behind it?

PTT Pcl is considering options for its nearly 38% stake in Taiwan-listed Lotus Pharmaceutical Co., including bringing in strategic partners to grow Lotus’s business across the Asia Pacific—particularly in Thailand and neighboring markets where PTT is primarily focused. The state-owned oil and gas company, which has been diversifying into life sciences, is working with advisers and is in early, preliminary stages of sounding out investor interest; a potential partnership could eventually lead to a full buyout of Lotus Pharmaceutical. PTT would prefer partners that can strengthen Lotus’s commercial presence in Southeast Asia and adjacent regions, aligning with PTT’s regional focus and broader expansion beyond traditional energy sectors.

What are Lotus Pharmaceutical’s core therapeutic areas, geographic operations, and recent financial performance as stated in the news?

Lotus Pharmaceutical develops generic medicines and biosimilars, with a primary focus on oncology and immunology. It has commercial operations across Southeast Asia, China, Japan, and South Korea, and maintains manufacturing facilities in Taiwan, South Korea, the US, and India—with its US site also serving as a research and development hub. For the six months through June, Lotus reported revenue of approximately $17.4 billion Taiwan dollars ($550 million) and net income of 1.2 billion Taiwan dollars. Its shares have declined 50% from a February peak, resulting in a market capitalization of $1.5 billion as of the report.

PTT Said to Consider Options for Taiwan-Listed Lotus Pharma

Sep 3, 2026

State-owned energy giant PTT is exploring strategic options for its stake in Taiwan-listed Lotus Pharmaceutical, potentially seeking partners to expand business in Asia Pacific markets. Preliminary deliberations could lead to a buyout of the drugmaker specializing in generic medicines and biosimilars.

bloomberg

2026-09-03

PTT Said to Consider Options for Taiwan-Listed Lotus Pharma

2026-09-07

Adnoc in Talks for Stakes in Thailand and Dangote Refineries

2026-09-15

PTT Clarifies Foreign Investment Stake Rumors in Refining Business

PTT Said to Consider Options for Taiwan-Listed Lotus Pharma

FAQ